Phathom Pharmaceuticals, Inc. PHAT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$157.3M+54.5% | -$221.25M+33.8% | -$274.55M+19.1% | -$330.15M-11.1% | -$345.79M-40.2% | ||
| $566K-25.3% | $633K-20.4% | $698K-11.3% | $733K+2.2% | $758K+17.9% | ||
| $28.71M+19.8% | $28.72M+19.4% | $29.8M-29.0% | $26.13M-38.4% | $23.96M-45.0% | ||
| $3.16M+31.0% | $3.01M+37.5% | $2.83M+33.1% | $2.65M+27.2% | $2.41M+30.1% | ||
| $44.36M+36.6% | $39.33M+5.8% | $34.74M+65.0% | $40.38M+271% | $32.48M+737% | ||
| —— | —— | —— | $20.17M+105% | $18.32M+85.9% | ||
| $37.94M+15.0% | $34.1M-2.4% | $26.47M+4.8% | $36.68M— | $32.99M— | ||
| $1.4M+212% | $1.22M— | -$7.64M— | -$8.55M— | $447K— | ||
| -$5M+4.8% | -$5.21M-2.1% | -$5.24M-13.8% | -$5.26M-42.8% | -$5.25M-90.4% | ||
| —— | —— | —— | —— | —— | ||
| -$97.49M+65.5% | -$166.78M+37.5% | -$225.23M+8.9% | -$274.69M-27.5% | -$282.68M-69.3% | ||
| $272K+141% | $229K+69.6% | $147K-75.7% | $164K-89.1% | $113K-92.3% | ||
| -$272K-141% | -$229K-69.6% | -$147K+75.7% | -$164K+89.1% | -$113K+92.3% | ||
| $173.25M+250% | $0-100% | $24.75M-66.5% | $24.75M-66.5% | $49.5M+0.6% | ||
| —— | —— | —— | —— | —— | ||
| $2.23M— | $1.64M— | $1.97M— | $1.66M— | —— | ||
| $66.35M-61.6% | -$288K-100% | $25.86M-93.0% | $148.18M-39.9% | $172.87M-52.4% | ||
| -$31.41M— | -$167.29M— | -$199.52M— | —— | —— | ||
| $21.08M+12.2% | $21.37M+23.6% | $20.75M+34.9% | $20.01M+46.7% | $18.78M+52.3% | ||
| —— | —— | —— | —— | $42.62M— | ||
| $3.16M+31.0% | $3.01M+37.5% | $2.83M+33.1% | $2.65M+27.2% | $2.41M+30.1% | ||
| —— | —— | —— | —— | $496K+25.3% | ||
| $192K+12.9% | $222K+26.9% | $173K-4.4% | $151K-18.4% | $170K-10.1% | ||
| —— | —— | —— | —— | $828K— | ||
| —— | —— | —— | —— | $1.74M— | ||
| -$5M+4.8% | -$5.21M-2.1% | -$5.24M-13.8% | -$5.26M-42.8% | -$5.25M-90.4% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| -$44K-198% | $0-100% | $59K— | $7K— | $45K— | ||
| $3.5M— | $0— | $750K— | $1.05M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$97.76M+65.4% | -$167M+37.4% | -$225.38M+9.0% | -$274.85M-26.7% | -$282.79M-67.9% | ||
| -$97.76M+65.4% | -$167M+37.4% | -$225.38M+9.0% | -$274.85M-26.7% | -$282.79M-67.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Phathom Pharmaceuticals, Inc. generate?
- Phathom Pharmaceuticals, Inc. (PHAT) generated -$97.5M in operating cash flow over the trailing twelve months.
- What is Phathom Pharmaceuticals, Inc.'s free cash flow?
- After $272.0K of capital expenditures, Phathom Pharmaceuticals, Inc.'s free cash flow was -$97.8M over the trailing twelve months, up 65.4% year over year.
- Where does Phathom Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
